Sangamo BioSciences | SGMO - Des Atouts





Des Atouts Changement Date
Alaunos Therapeutics USD 1.88M 1.08M 2026-03
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Amgen USD 95.64B 3.14B 2026-06
Bayer EUR 107.29B 659M 2026-06
BioCryst Pharmaceuticals USD 557.85M 92.8M 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 145.86M 10.71M 2026-03
CSL USD 37.9B 1.5B 2025-12
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Grifols EUR 23.15B 142.7M 2025-12
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
J&J USD 201.06B 167M 2026-06
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Merck USD 129.8B 1.12B 2026-06
Novartis USD 122.03B 3.5B 2026-06
Omeros USD 200.57M 34.59M 2025-06
Pfizer USD 201.13B 6.49B 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 129.06B 1.04B 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Tectonic Therapeutic USD 246.58M 14.46M 2026-03
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06